JP2020508961A - Ｓｇｌｔ１／２阻害剤の投与レジメン - Google Patents

Ｓｇｌｔ１／２阻害剤の投与レジメン Download PDF

Info

Publication number
JP2020508961A
JP2020508961A JP2018547979A JP2018547979A JP2020508961A JP 2020508961 A JP2020508961 A JP 2020508961A JP 2018547979 A JP2018547979 A JP 2018547979A JP 2018547979 A JP2018547979 A JP 2018547979A JP 2020508961 A JP2020508961 A JP 2020508961A
Authority
JP
Japan
Prior art keywords
treatment
study
subject
lik066
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018547979A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020508961A5 (https=
Inventor
リン キーフ，デボラ
リン キーフ，デボラ
シャオ，チィン
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2020508961A publication Critical patent/JP2020508961A/ja
Publication of JP2020508961A5 publication Critical patent/JP2020508961A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018547979A 2017-03-03 2018-03-02 Ｓｇｌｔ１／２阻害剤の投与レジメン Pending JP2020508961A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762466572P 2017-03-03 2017-03-03
US62/466,572 2017-03-03
PCT/IB2018/051350 WO2018158744A1 (en) 2017-03-03 2018-03-02 Sglt1/2 inhibitor lik066 for treating obesity

Publications (2)

Publication Number Publication Date
JP2020508961A true JP2020508961A (ja) 2020-03-26
JP2020508961A5 JP2020508961A5 (https=) 2021-03-18

Family

ID=61656084

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018547979A Pending JP2020508961A (ja) 2017-03-03 2018-03-02 Ｓｇｌｔ１／２阻害剤の投与レジメン

Country Status (5)

Country Link
US (1) US10952989B2 (https=)
JP (1) JP2020508961A (https=)
AR (1) AR111161A1 (https=)
TW (1) TW201834663A (https=)
WO (1) WO2018158744A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5384744B2 (ja) * 2009-10-20 2014-01-08 ノバルティス アーゲー グリコシド誘導体およびその使用
JP2014511874A (ja) * 2011-04-14 2014-05-19 ノバルティス アーゲー グリコシド誘導体および糖尿病の処置のためのその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5384744B2 (ja) * 2009-10-20 2014-01-08 ノバルティス アーゲー グリコシド誘導体およびその使用
JP2014511874A (ja) * 2011-04-14 2014-05-19 ノバルティス アーゲー グリコシド誘導体および糖尿病の処置のためのその使用

Also Published As

Publication number Publication date
US20200121639A1 (en) 2020-04-23
US10952989B2 (en) 2021-03-23
TW201834663A (zh) 2018-10-01
AR111161A1 (es) 2019-06-12
WO2018158744A1 (en) 2018-09-07

Similar Documents

Publication Publication Date Title
Chen et al. Risk factors for sarcopenia in the elderly with type 2 diabetes mellitus and the effect of metformin
Pascart et al. Gout: state of the art after a decade of developments
Christen-Zaech et al. Pediatric morphea (localized scleroderma): review of 136 patients
Astrup et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
Jansen et al. Diabetes-related distress, insulin dose, and age contribute to insulin-associated weight gain in patients with type 2 diabetes: results of a prospective study
Jenssen et al. The gap between guidelines and practice in the treatment of type 2 diabetes: a nationwide survey in Norway
Mafauzy Diabetes control and complications in public hospitals in Malaysia
TW201642899A (zh) 甘精胰島素／利司那肽固定比率配製劑
Bitnun et al. Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naive HIV-infected children
JP2020090508A (ja) Ｄｇｌａを含む薬学的組成物及びその使用
JP2018503644A (ja) リキシセナチドを用いた小児２型真性糖尿病患者の治療
Witham et al. Does oral sodium bicarbonate therapy improve function and quality of life in older patients with chronic kidney disease and low-grade acidosis (the BiCARB trial)? Study protocol for a randomized controlled trial
Ghosh et al. Churchill's Pocketbook of Diabetes E-Book
JP2021532104A (ja) 多発性硬化症の治療及び予防方法における使用のための置換されたアミノ−ピリミジン化合物
JP2020508961A (ja) Ｓｇｌｔ１／２阻害剤の投与レジメン
Heimann et al. Pep19: A Novel Approach for Reducing Visceral Fat and Improving Sleep Quality in Obese Adults—Results From an Early‐Stage Clinical Trial
Cokro et al. Effects of SGLT2 Inhibitors Compared with Sulfonylurea on Glycaemic Control and Cardiovascular Risk Reduction in Asia: Meta-Analysis.
Dikko et al. Determination of Oral Glucose Tolerance (OGT) of benign prostatic hyperplasia patients treated with tamsulosin in Sokoto state, Nigeria
Bacchetti et al. Fat distribution in women with HIV infection
Snaith et al. Statistical Analysis Plan for the INTIMET study (Insulin Resistance in Type 1 Diabetes Managed with Metformin)
Glezerman et al. Gender and Sex Conscious Medicine and the future direction of health care: An invited scientific review by the European Board and College of Obstetrics and Gynaecology (EBCOG)
Hatem et al. Drug-related Problems Among Type 2 Diabetic Patients With Hypertension in a Tertiary Care Hospital in Lebanon: A Cross-sectional Study
Zubair et al. Assessment of BMI, Duration of Diabetes, Fasting lipids, S. Creatinine and Microalbuminuria in Glycemic Control: A 10 year’s follow-up study
ALI et al. Anti-Hypertensive treatment guidelines, result and their evaluation.
Ismail et al. Evaluating the Effect of Prebiotics on the Gut Microbiome Profile and β-cell Function in Youth with Newly-Diagnosed Type 1 Diabetes: Protocol of a Randomized Controlled Trial

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220405

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221101